Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alterity Therapeutics Limited - American Depositary Shares (NQ:ATHE)

3.430 -0.050 (-1.44%)
Streaming Delayed Price Updated: 12:42 PM EST, Feb 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alterity Therapeutics Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Raises A$40.0 million in Placement
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Wondering what's happening in today's after-hours session? ↗
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today. 
Via Chartmill
News headline image
Nasdaq Moves Lower; Meta Platforms Posts Strong Sales ↗
 
Via Benzinga
News headline image
What's Going On With Alterity Therapeutics Shares Thursday? ↗
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy. 
Via Benzinga
News headline image
Dow Jumps Over 100 Points; Tesla Earnings Miss Views ↗
 
Via Benzinga
Topics Earnings Stocks
News headline image
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars ↗
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo. 
Via Stocktwits
News headline image
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron – 
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders®
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Appendix 4C – Q4 FY24 Quarterly Cash Flow Report
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present at MST Financial Webinar
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
From ALTERITY THERAPEUTICS LIMITED
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.